Abstract
Pharmaceutical industry funding has transformed much grassroots community activism on health into corporate-sponsored advocacy. This critical commentary outlines recent evidence about industry funding of patient advocacy groups, offers a commentary on the history of grassroots activism appearing in this issue of the journal, and calls for greater scrutiny of the impacts and ethics of such sponsorship.
Original language | English |
---|---|
Pages (from-to) | 61-63 |
Number of pages | 3 |
Journal | Journal of Bioethical Inquiry |
Volume | 17 |
Issue number | 1 |
Early online date | 24 Mar 2020 |
DOIs |
|
Publication status | Published - Mar 2020 |